Correlation Between Serum Globulin/Cholinesterase and Clinical Prognosis of Patients with Multiple Myeloma
Objective To analyze the relationship between the ratio of serum globulin(G)to cholinesterase(CHE)(G/C)and the clinical prognosis of multiple myeloma(MM)patients.Methods A total of 87 patients with primary MM admitted to Xuchang Central Hospital from May 2018 to May 2022 were included in the study,and they were followed up for 12 months.According to the clinical prognosis of patients,they were divided into poor prognosis group and good prognosis group.Serum G and CHE levels were measured and G/C values were calculated at admission.Clinical data and other laboratory indicators were collected and compared at admission,and the correlation between G/C values and the clinical prognosis of MM patients was analyzed.Results Following up for 12 months,31 out of 87 MM patients had poor prognosis,including 21 cases of recurrence and 10 cases of progression,with a poor prognosis rate of 35.63％.There were statistical significant differences in age,international staging system(ISS)stage,G/C value and β2 microglobulin level between the two groups(P＜0.05).There was no statistical significant difference in other clinical data between the two groups(P＞0.05).The results of multivariate logistic regression analysis showed that age,ISS stage,serum G/C and β2 microglobulin were the influencing factors of poor prognosis in MM patients(P＜0.05).The receiver operating characteristic(ROC)curve was drawn.The results showed that the predictive value of age and ISS stage in predicting poor clinical prognosis of MM patients was not high(area under the curve＜0.7).The area under the curve of G/C value and β2 microglobulin level in predicting poor clinical prognosis of MM patients were both＞0.7,with certain predictive value,and the predictive value of G/C value was higher(area under the curve was 0.804).Conclusion A high G/C value at initial diagnosis indicates poor prognosis in MM patients,and has certain predictive value for early disease progression in MM patients.
万方数据
维普
